Test offers new way to personalize treatment, reduce unnecessary chemotherapy for patients with breast cancer

A new cancer diagnostic test marketed by Veracyte and developed by a group of researchers, including UNC geneticist Charles Perou, Ph.D., has been found to accurately predict whether patients with breast cancer need chemotherapy or whether hormone therapy alone can safely and effectively lead to remission. ...